<DOC>
	<DOC>NCT00725452</DOC>
	<brief_summary>Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.</brief_summary>
	<brief_title>Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)</brief_title>
	<detailed_description>This study population was chosen from a non-probability sample.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>According to the European Summary of Product Characteristics (SPC): Adult subjects with moderatetosevere plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapy including cyclosporine, methotrexate, or PsoralenultravioletA light (PUVA). According to the European SPC: Subjects with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections. Subjects with moderatetosevere heart failure (New York Heart Association (NYHA) class III/IV). Subjects with a history of hypersensitivity to Infliximab or to other murine proteins or to any of the excipients. Subjects with elevated liver enzymes (&gt;5 upper limit of normal (ULN)).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>